Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Amgen (AMGN) shares have declined 1.8% over the past month, underperforming the broader S&P 500 and its industry, despite holding a Zacks Rank #3 (Hold) which suggests expected in-line market performance. Analysts project current quarter EPS of $5.00 (-10.4% YoY) and full-year EPS of $21.08 (+6.3% YoY), though estimates have experienced minor downward revisions recently. The biotech giant has a strong history of exceeding expectations, beating EPS estimates in the last four quarters and revenue in three, and its Zacks Value Style Score of 'B' indicates it trades at a discount relative to peers.

Analysis

Amgen (AMGN) shares have recently underperformed, declining -1.8% over the past month, significantly lagging the S&P 500's +2.1% gain and the broader industry's +8.7% increase. Despite this, the stock holds a Zacks Rank #3 (Hold), which typically suggests an expectation of near-term performance in line with the broader market, indicating a mixed outlook. This underperformance occurs even as the stock is heavily searched by Zacks.com visitors.

Analyst consensus projects a -10.4% year-over-year decline in current quarter EPS to $5.00, with a slight -0.9% downward revision over the last 30 days. However, full fiscal year EPS is expected to grow +6.3% to $21.08, while current quarter revenue is forecast to increase +5.2% to $8.94 billion. Forward estimates indicate a deceleration in growth for the next fiscal year, with EPS growth slowing to +1.7% and revenue growth to +1.8%.

Amgen has demonstrated a strong track record of exceeding expectations, beating consensus EPS estimates in all of the last four quarters and revenue estimates in three. In the last reported quarter, revenues of $9.18 billion surpassed estimates by +3.52%, and EPS of $6.02 beat by +14.45%. Furthermore, the company's Zacks Value Style Score of 'B' suggests it is currently trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should consider Amgen's recent market underperformance in contrast to its consistent history of beating earnings estimates and its current valuation discount.
• Monitor upcoming earnings reports closely, particularly the projected -10.4% EPS decline for the current quarter, to assess if recent downward estimate revisions stabilize or reverse.
• Evaluate the sustainability of Amgen's future revenue and earnings growth, especially the projected deceleration in the next fiscal year, against its current attractive valuation relative to peers.